MedTrace Logo

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

NCT06561347 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-03-31

No results posted yet for this study

Summary

The purpose of this study is to determine the very good partial response (VGPR) or better rate in participants with Waldenström macroglobulinemia (WM).

The names of the study drugs involved in this study are as follows: zanubrutinib, bendamustine, and rituximab.

Conditions

Interventions

DRUG

Zanubrutinib

A potent, specific, and irreversible Bruton tyrosine kinase (BTK) inhibitor

DRUG

Bendamustine

Alkylating agent

DRUG

Rituximab

Monoclonal antibody

Sponsors & Collaborators

  • BeiGene

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Andrew Branagan, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-20
Primary Completion
2026-12-01
Completion
2027-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06561347 on ClinicalTrials.gov